ArticleJournal of inflammation research2026
Exploring Centrosome Amplification-Associated Biomarkers in Osteoarthritis Through Bioinformatics and Experimental Approaches.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to identify centrosome amplification-related genes (CA-RGs) as potential biomarkers in osteoarthritis (OA). Methods: Publicly available databases provided the transcriptome datasets for OA, while a well-established list of CA-related genes was obtained from published resources. A comprehensive computational biology strategy was implemented, integrating differential gene expression profiling, weighted gene co-expression network analysis (WGCNA), Mendelian randomization (MR) analysis, and ROC curve evaluation to screen for potential diagnostic markers. Following this, a predictive nomogram was developed, accompanied by gene set enrichment analysis (GSEA) and immune cell infiltration characterization utilizing the identified biomarkers. Additionally, single-cell RNA sequencing (scRNA-seq) datasets were examined to determine critical cell subpopulations and track biomarker expression patterns across different cell types. Ultimately, clinical specimen analysis through RT-qPCR was conducted to experimentally confirm the expression profiles of these biomarkers. Results: PLK2 and SUN2 were identified as biomarkers. A nomogram model based on them demonstrated high predictive accuracy for OA. GSEA indicated both biomarkers were strongly correlated with lysosomal pathways. Immune infiltration analysis revealed significant differences in 16 immune cell types between OA and control groups. scRNA-seq analysis pinpointed two key cell clusters: preinflammatory chondrocytes (preInfC) and hypertrophic chondrocytes (HTC). Pseudotime trajectory analysis further uncovered dynamic expression patterns: PLK2 showed a sustained increase in HTC, while SUN2 displayed a dip then rise. In preInfC, PLK2 expression fluctuated (increase-decrease-increase), whereas SUN2 rose initially then declined. Conclusion: This study identified 2 biomarkers associated with CA and explored their underlying mechanisms of action, providing new insights into potential therapeutic strategies for OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.